Benefits Of Telemedicine And Telehealth And How These Concepts Can Drive The Healthcare Industry?
Technology is making significant advancements in any and every industry and healthcare turns out to…
Technology is making significant advancements in any and every industry and healthcare turns out to…
Symantec combines global threat intelligence with Google Cloud’s gen AI expertise to simplify threat analysis…
Focused on the Unique Security Needs of Healthcare: It Ensures Seamless and Protected Access for…
Symantec combines global threat intelligence with Google Cloud’s gen AI expertise to simplify threat analysis…
Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children…
Deconvolution Analysis Shows 60% Increase in GH Secretion, Comparable to Established Values in Normal Children…
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational,…
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational,…
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is…
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is…
Synfini Unites Neuro-Symbolic AI, Robotic Automation, and World-class Chemistry Data to Dramatically Accelerate Drug Discovery; Company Leverages More Than $40 Million in Non-dilutive…
Synfini Unites Neuro-Symbolic AI, Robotic Automation, and World-class Chemistry Data to Dramatically Accelerate Drug Discovery; Company Leverages More Than $40 Million in Non-dilutive…
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first…
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first…
– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development…
– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development…
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (NASDAQ:…
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (NASDAQ:…
–Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population…
Lixte Biotechnology Holdings, Inc. Bas van der Baan, Newly Appointed President, CEO, Vice Chairman, LIXTE…